UroGen Pharma, a biotechnology company developing and commercializing solutions that treat urothelial and specialty cancers, today announced a strategic agreement and a related equity investment agreement with IntraGel Therapeutics.
UroGen also will invest up to $7 million in IntraGel.
The deal includes two strategic components. First, UroGen gains access to IntraGel's proprietary SRGel platform, a biodegradable, sustained-release formulation technology designed for localized drug delivery, through a research license and options to obtain an exclusive, worldwide license to develop and commercialize up to three additional oncology products combining the SRGel platform with compounds to be designated by UroGen.
Second, UroGen receives an exclusive option to obtain an exclusive, worldwide license to develop and commercialize TumoCure, IntraGel’s investigational therapy for advanced head and neck cancer, following IntraGel's completion of a Phase 2 clinical study.
"This option agreement represents an important step in expanding UroGen's oncology pipeline and technological capabilities," said UroGen CEO Liz Barrett in a statement. "IntraGel's biodegradable, sustained-release technology complements our expertise in local drug delivery while creating significant optionality for future innovation. Beyond the opportunity to advance TumoCure following a Phase 2 clinical study, we believe the SRGel technology could potentially enable multiple therapeutic approaches across a range of solid tumors and provide a foundation for new product opportunities over time."
SRGel is a biodegradable depot technology designed to enable sustained local release of therapeutic agents over extended periods. The platform's flexibility supports multiple therapeutic modalities and has potential applicability across a broad range of solid tumor settings.
TumoCure is an investigational cisplatin treatment formulated with IntraGel’s proprietary SRGel platform, designed to enable prolonged localized drug exposure while limiting systemic exposure.
